[go: up one dir, main page]

WO2007067512A3 - Method for identifying modulators of adprh useful for treating alzheimer's disease - Google Patents

Method for identifying modulators of adprh useful for treating alzheimer's disease Download PDF

Info

Publication number
WO2007067512A3
WO2007067512A3 PCT/US2006/046331 US2006046331W WO2007067512A3 WO 2007067512 A3 WO2007067512 A3 WO 2007067512A3 US 2006046331 W US2006046331 W US 2006046331W WO 2007067512 A3 WO2007067512 A3 WO 2007067512A3
Authority
WO
WIPO (PCT)
Prior art keywords
adprh
useful
disease
treating alzheimer
identifying modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/046331
Other languages
French (fr)
Other versions
WO2007067512A2 (en
Inventor
John M Majercak
William J Ray
David J Stone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of WO2007067512A2 publication Critical patent/WO2007067512A2/en
Publication of WO2007067512A3 publication Critical patent/WO2007067512A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Methods for identifying modulators of ADPRH are described. The methods are particularly useful for identifying analytes that antagonize ADPRH 's effect on processing of amyloid precursor protein to AjS peptide and thus useful for identifying analytes that can be used for treating Alzheimer disease.
PCT/US2006/046331 2005-12-08 2006-12-04 Method for identifying modulators of adprh useful for treating alzheimer's disease Ceased WO2007067512A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74846505P 2005-12-08 2005-12-08
US60/748,465 2005-12-08

Publications (2)

Publication Number Publication Date
WO2007067512A2 WO2007067512A2 (en) 2007-06-14
WO2007067512A3 true WO2007067512A3 (en) 2007-12-13

Family

ID=38123413

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/046331 Ceased WO2007067512A2 (en) 2005-12-08 2006-12-04 Method for identifying modulators of adprh useful for treating alzheimer's disease

Country Status (1)

Country Link
WO (1) WO2007067512A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2603524A1 (en) 2010-08-14 2013-06-19 AbbVie Inc. Amyloid-beta binding proteins

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030082511A1 (en) * 2001-09-25 2003-05-01 Brown Steven J. Identification of modulatory molecules using inducible promoters
US20030200555A1 (en) * 2001-05-22 2003-10-23 Hazuda Daria Jean Assays using amyloid precursor proteins with modified beta-secretase cleavage sites to monitor beta-secretase activity
US20050019330A1 (en) * 1997-12-02 2005-01-27 Neuralab Limited Prevention and treatment of amyloidogenic disease
WO2005098433A2 (en) * 2004-04-01 2005-10-20 Novartis Ag Diagnostic assays for alzheimer’s disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050019330A1 (en) * 1997-12-02 2005-01-27 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20030200555A1 (en) * 2001-05-22 2003-10-23 Hazuda Daria Jean Assays using amyloid precursor proteins with modified beta-secretase cleavage sites to monitor beta-secretase activity
US20030082511A1 (en) * 2001-09-25 2003-05-01 Brown Steven J. Identification of modulatory molecules using inducible promoters
WO2005098433A2 (en) * 2004-04-01 2005-10-20 Novartis Ag Diagnostic assays for alzheimer’s disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LOVE ET AL.: "Increased poly(ADP-ribosyl)ation of nuclear proteins in Alzheimer's disease", BRAIN, vol. 122, 1 February 1999 (1999-02-01), pages 247 - 253, XP002233086 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US9394360B2 (en) 2006-11-30 2016-07-19 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins

Also Published As

Publication number Publication date
WO2007067512A2 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
WO2008076262A3 (en) Receptor for amyloid beta and uses thereof
WO2006138659A3 (en) Intranasal red light probe for treating alzheimers disease
WO2007064972A3 (en) Monoclonal antibodies against amyloid beta protein and uses thereof
EP1877175A4 (en) DEVICE AND METHOD FOR THE PRODUCTION OF RADIOPHARMAZEUTIKA
DE60332024D1 (en) PROCESS FOR THE PREPARATION OF SOY PROTEIN
WO2009098682A3 (en) Methods and compositions for treatment of mitochondrial disorders
WO2007001264A3 (en) Method of making recombinant human antibodies for use in biosensor technology
DE60237242D1 (en) ASSISTANCE PROCEDURE, ASSISTANCE PROGRAM AND ASSISTANCE TO PICTURE ANALYSIS
WO2006099610A3 (en) Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy
DE60327074D1 (en) FLUOROBENZAMIDE FOR THE TREATMENT OF ALZHEIMER OR SENILER DEMENTIA
EP1668125A4 (en) MODIFIED ENZYMES, METHOD FOR THE PRODUCTION OF MODIFIED ENZYMES AND USES THEREOF
WO2007070604A3 (en) System and method for providing high speed content and services
DE602004018249D1 (en) Process for the dearomatization of whey protein
WO2004093790A3 (en) Yeast ectopically expressing abnormally processed proteins and uses therefor
WO2007067512A3 (en) Method for identifying modulators of adprh useful for treating alzheimer's disease
WO2007008073A3 (en) METHODS FOR DETERMINING THE EFFECT OF A TREATMENT ON THE CROSS-ß STRUCTURE CONTENT OF A PROTEIN; SELECTION OF TREATMENTS AND USES THEREOF
WO2007019312A3 (en) Methods for characterizing and treating cognitive impairment in aging and disease
DE60220554D1 (en) MICROWAVE-INDUCED PROCESS FOR THE PRODUCTION OF SUBSTITUTED 4-VINYLPHENOLES
DE602005013895D1 (en) Device for the production of tire components.
WO2007010110A3 (en) Method for detecting aggregate-forming circulating protein forms and agent for capturing formed aggregates
DE602006003094D1 (en) 4-PHENYL-5-OXO-1,4,5,6,7,8-HEXAHYDROCHINOLINE DERIVATIVES FOR THE TREATMENT OF BARRENESS
DE602005013650D1 (en) PROTEIN HYDROLYSATE FOR THE TREATMENT OF TIREDNESS
EP1870457A4 (en) DIPEPTIDE CRYSTAL AND METHOD FOR THE PRODUCTION THEREOF
WO2006138363A3 (en) Method for identifying modulators of keah6 useful for treating alzheimer's disease
WO2008017017A3 (en) Three-phase partitioning method for purifying a protein

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06847499

Country of ref document: EP

Kind code of ref document: A2